API
Roxithromycin
KDMF APIs
Roxithromycin
Korean name | 록시트로마이신 |
|---|---|
Category | Antibiotic preparations |
CAS No. | 80214-83-1 |
KDMF registration No. | 20050831-9-A-2-02(12) |
Manufacturer | Zhejiang Zhenyuan Pharmaceutical Co. Ltd. |
Specification | EP/In-house |
Product information
IUPAC Name | (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-10-(2,4,7-trioxa-1-azaoctan-1-ylidene)-1-oxacyclotetradecan-2-one |
|---|---|
Synonyms | (9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime) |
Description | Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin . It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila . Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. |
Certificate of Analysis | If you need more information, please contact us. |
If you need additional documents such as specifications or certificates of analysis, please request them together with your inquiry. Our team will review and reply. (02-579-1056 · ace@acebiopharm.com)